depression

Tucked in the Q2 earnings release, Sage Therapeutics Inc (NASDAQ: SAGE) has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder (MDD). What Happened: After talks with the FDA, the decision led the Company to believe it can seek approval without the...

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced positive top-line results from the human abuse potential (HAP) study with REL-1017 for major depressive disorder (MDD).  Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in...

Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application sought approval to start a Phase 1/2a basket study designed to test...

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major Depressive Disorder (MDD). The 543-subject trial met its primary endpoint with...

Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD). The target action date is set at August 22. AXS-05 (dextromethorphan-bupropion) is an oral, investigational NMDA...

Mind Medicine (MindMed) Inc (OTC: MMEDF), a medicine biotech company in psychedelics, on Wednesday announced its start of the first-ever clinical trial measuring and evaluating 3,4-methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) combinations in the human body, at the...

In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential...

Johnson & Johnson (NYSE: JNJ) received encouraging news after a FDA panel decision went its way with respect to its treatment-resistant depression drug. Panel Finds Risk-Benefit Favorable A joint committee of the FDA's Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk...

Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) and SAGE Therapeutics Inc (NASDAQ: SAGE) were moving sharply higher Monday on separate clinical trial results.  Axsome's Major Depressive Disorder Drug Trial Axsome said its lead pipeline asset AXS-05 met its primary endpoint of...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg Thalmann. The Analyst Analyst Michael Higgins initiated coverage of Marinus...

Sage Therapeutics Inc (NASDAQ: SAGE) is a buy ahead of the commercial launch of its safer alternatives to existing antidepressants, according to Ladenburg Thalmann. The Analyst Ladenburg Thalmann's Michael Higgins initiated coverage of Sage Therapeutics' stock with a Buy rating and $...

Shares of Alkermes Plc (NASDAQ: ALKS) lost more than 20 percent early Monday morning after the U.S. Food and Drug Administration said it won't review the company's therapy ALKS-5461. What Happened Alkermes, which mostly focuses on treatments for central nervous system diseases, said...

Anyone battling depression knows just how heavy of a burden it can be and how difficult it can make even the basic parts of everyday life. However, if there were ever a silver lining to a debilitating condition, mild to moderate depression may actually make you a better investor. According to...

The holiday season can be an exciting and fulfilling time of year for people to disrupt their standard routines and spend time reflecting with family and friends. Unfortunately, for many Americans, the holiday season is instead be filled with stress, anxiety and depression. From a psychological...

Researchers at the University of Toledo have found a link between extended television “binge watching” and both depression and anxiety. Binge watching has become increasingly popular since Netflix, Inc. (NASDAQ: NFLX) has begun making entire new seasons of hit shows like "House of...